Zhang Xin-Jie, Lou Jian
Department of Cancer Center, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, Zhejiang Province, China.
World J Gastrointest Oncol. 2024 Mar 15;16(3):1084-1090. doi: 10.4251/wjgo.v16.i3.1084.
The advanced first-line regimen for advanced gastric cancer is based on a combination of fluoropyrimidine and platinum and/or paclitaxel (PTX), forming a two- or three-drug regimen. Compared to conventional PTX, nanoparticle albumin-bound PTX (Nab-PTX) has better therapeutic effects and fewer adverse effects reported in studies. Nab-PTX is a great option for patients presenting with advanced gastric cancer. Herein, we highlight an adverse event (hemorrhagic cystitis) of Nab-PTX in advanced gastric cancer.
A 55-year-old male was diagnosed with lymph node metastasis after a laparoscopic-assisted radical gastrectomy for gastric cancer that was treated by Nab-PTX and S-1 (AS). On the 15 day after treatment with AS, he was diagnosed with hemorrhagic cystitis.
Physicians should be aware that hemorrhagic cystitis is a potential adverse event associated with Nab-PTX treatment.
晚期胃癌的一线先进方案基于氟嘧啶与铂和/或紫杉醇（PTX）联合使用，形成两药或三药方案。与传统PTX相比，纳米白蛋白结合型紫杉醇（Nab-PTX）在研究中显示出更好的治疗效果且不良反应更少。Nab-PTX是晚期胃癌患者的一个很好的选择。在此，我们强调了Nab-PTX在晚期胃癌中引起的一种不良事件（出血性膀胱炎）。
一名55岁男性在接受腹腔镜辅助胃癌根治术后被诊断为淋巴结转移，接受了Nab-PTX和S-1（AS）治疗。在接受AS治疗后的第15天，他被诊断为出血性膀胱炎。
医生应意识到出血性膀胱炎是与Nab-PTX治疗相关的潜在不良事件。
